Breaking News

U.S. Sets Penalty Duties on Steel Pipe From South Korea, Eight Other Nations, to Counter Dumping
Tweet TWEET

Harvard Bioscience to Participate in Press Conference Today to Discuss Landmark Surgery

Harvard Bioscience to Participate in Press Conference Today to Discuss
Landmark Surgery

Team Involved in the Surgery to Address Media Only Today at 11:00 a.m. ET

HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range
of tools to advance life science research and regenerative medicine, will
participate in a press conference today at 11:00 a.m. ET regarding its
involvement in a landmark surgery that involved materials manufactured by
Harvard Apparatus Regenerative Technology, the wholly owned regenerative
medicine technology subsidiary of Harvard Bioscience. David Green, Harvard
Bioscience's President, will be present and available for questions from the
media.

Those interested in listening to the press conference may dial-in via phone at
(309) 624-1000 or (855) 749-6781. Conference ID: 475283.

A subsequent press release will be issued later this morning that will
disclose greater detail.

About Harvard Bioscience

Harvard Bioscience, or HBIO, is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
HBIO sells its products to thousands of researchers in over 100 countries
primarily through its 850 page catalog (and various other specialty catalogs),
its website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via our field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6426

About Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology, Inc., a wholly owned subsidiary of
Harvard Bioscience, develops and manufactures devices for use within the
emerging field of regenerative medicine. These devices include bioreactors and
synthetic scaffolds for growing tissue and organs outside the body; and
injectors for stem cell therapy.

Registration Statement of Harvard Apparatus Regenerative Technology, Inc.

A registration statement including a prospectus relating to the common stock
of Harvard Apparatus Regenerative Technology, Inc. has been filed with the SEC
but has not yet become effective. These securities may not be sold nor may
offers to buy these securities be accepted before the time the registration
statement becomes effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are
made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include
statements relating to, among other things, activities of Harvard Bioscience
and the postponed IPO and other activities of Harvard Apparatus Regenerative
Technology. These statements involve risks and uncertainties, including among
other things, market conditions that may cause results to differ materially
from the statements set forth in this press release. The forward-looking
statements in this press release speak only as of the date of this press
release. Harvard Bioscience expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to such statements to reflect any
change in its expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is based.

CONTACT: David Green, President
         dgreen@harvardbioscience.com
        
         Tom McNaughton, CFO
         tmcnaughton@harvardbioscience.com
        
         Chane Graziano, CEO
         cgraziano@harvardbioscience.com
         Tel: 508 893-8999
         Fax: 508 892-6135
        
         Dian Griesel Inc.
         Investors:
         Cheryl Schneider
         212-825-3210
         cschneider@dgicomm.com
        
         Media:
         Laura Radocaj
         212-825-3210
         lradocaj@dgicomm.com

Harvard Bioscience, Inc. Logo